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Summary In a one-year follow-up study, 444 blood histamine determinations were performed in 163 patients
with solid malignant tumours. Compared with normal subjects, blood histamine levels were significantly
lower in patients with unresected primary tumours (30.7 +19.9 ngml-), metastases (34.1 + 17.1 ngml-), or
both (24.5+12.8ngml-1). By contrast, after successful tumour resection, histamine blood levels were nearly
normal (52.1 +18.4 ngml-, versus 59.6+22.6 in control patients). Stability of the histamine blood levels was
associated with stability of the disease. A progressive decrease in histamine blood levels preceded clinical
relapse or detection of metastasis. In patients with consecutive histamine blood levels which were
< 15 ngml- 1, survival did not exceed 2 months.
In patients with gastrointestinal tumours, blood histamine levels provided information additional to that
derived from serum CEA determination. In patients with non-gastrointestinal tumours, the blood histamine
level may be of more value than CEA as a marker of disease progression.
Numerous clinical surveys have shown that the
atopic population has a decreased risk of
malignancy and that a decreased prevalence of
immediate hypersensitivity has been observed in
cancer populations (Fisherman, 1960; McKay.
1966; Ure, 1969; Meers, 1973; Alderson, 1974;
Allegra et al., 1976). The rare occurrence of allergic
diseases in cancer patients cannot be explained by a
decrease in IgE synthesis. In cancer patients, IgE
levels are variable. High levels (Arbesman et al.,
1973; Ford, 1978; Hallgren et al., 1981; Blondal &
Nou, 1981), normal levels (Serrou et al., 1975;
Pauwels & Van Der Straeten, 1975), or low values
(Augustin & Chandradasa, 1971; Jacobs et al.,
1972) have been found. Questionable criteria for
atopy might perhaps explain why some authors do
not endorse the negative association between atopy
and malignant disease (Logan & Saker, 1953;
McKee et al., 1967; Hugues & Raitz, 1979).
The inverse relationship between anaphylaxis and
malignant tumours is also supported by
experimental data. In fibrosarcoma-bearing mice,
the intensity of anaphylactic response (local or
general and active or passive) was shown to be less
intense than in normal mice. The tumour-associated
inhibitory effect on active systemic anaphylaxis was
exerted mainly on events occurring after
homocytotropic antibody synthesis, since the serum
titres of these antibodies were comparable in
normal and tumour-bearing animals (Lynch &
Salomon, 1977). In these fibrosarcoma-bearing
Correspondence: C. Burtin.
Received 28 September 1982; accepted 18 November 1982.
mice, we showed that tissue histamine levels were
significantly higher (1.5-3-fold) than in normal mice
(Scheinmann et al., 1979; Burtin et al., 1981a) but
that histamine availability was reduced (Burtin et
al., 1981b; 1982).
These data led us to evaluate blood histamine
levels in cancer patients, a study which has never
been previously undertaken. We attempted to
correlate the results with those of the assay of
carcinoembryonic antigen (CEA) in serum from the
same patients.
Materials and methods
I. Subjects
A. Cancer patients
All patients (163 cases) were hospitalized for
nutritional problems and medical supervision before
or after surgical treatment (tumour resection or
palliative intervention). Patients who had received
cancer chemotherapy or radiotherapy during the
preceding year were excluded from this study as
well as patients on corticosteroids (Saavedra-
Delgado et al., 1980). The follow-up study was
performed for between 1 month and 1 year.
Clinical status allowed the division into 4 groups
(Table I).
a) Group I: Presence of unresected primary cancer
without known metastasis One hundred and fifteen
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Table I Localization of the primary tumour in 163 cancer patients
Group I Group 11 Group III Group IV
n=40 n=44 n=40 n=39
Tongue 3 2 2
Pharynx-Larynx 2 5 4 1
Oesophagus 11 4 9 5
Stomach 3 8 12 8
Colon 2 5 6 7
Rectum 2 1 4
Liver 2
Gall-bladder 2
Pancreas 11 3
Kidney 1
Ureter I
Bladder 1 2 3 2
Prostate 2 1 1
Breast 1 2 4
Uterus 1 5 2 5
Lung 2
Unknown 3
Group I Presence of unresected primary cancer without known metastasis.
Group II: Presence of unresected primary cancer and metastasis.
Group III: Resected primary tumour without known metastasis.
Group IV: Resected primary tumour and metastasis.
blood histamine determinations were performed on
40 patients (13 females and 27 males, age range 19-
83yrs). All these tumours proved to be surgically
unresectable for anatomical and/or physiological
reasons. At the time of the first determination,
primary cancer had been diagnosed from 1 month
to 2 years previously. Twenty-two patients died
during the study.
b) Group II: Presence of unresected primary cancer
and metastasis One hundred and thirteen blood
histamine determinations were performed on 44
patients (20 females and 24 males, age range 33-
88 yrs). Metastases were localized in the liver (18
cases), lungs (18), bone (8), peritoneum (6), skin (3)
and brain (1). Ten patients had metastases in 2
sites.
At the time of the first determination, the
primary cancer had been diagnosed from one
month to 6 years earlier, and the presence of
metastasis was known from 1-3 months earlier.
Thirty one patients died during the study.
c) Group III. Surgical excision of the primary
tumour without known metastasis Ninety-three
blood histamine levels were studied on 40 patients
(17 females and 23 males, age range 43-90yrs). The
first determination was performed from one month
to 14 months after the successful intervention. All
but 2 of these patients were discharged and took up
normal activity. Two patients died, the first one of
liver metastasis and the second after a local relapse
of primary cancer.
d) Group IV: Surgical excision of the primary
tumour and presence of metastasis One hundred
and three blood histamine determinations were
performed on 39 patients (22 females and 17 males,
age range 38-86yrs). Metastasis were found in the
liver (19 cases), lung (10), bone (8), lymph nodes
(9), skin (2), peritoneum (3) and brain (1). Five
patients had metastases at 2 sites and 4 patients at
three. Patients were studied between 1 month and 4
years after tumour excision and between 1 month
and 1 year after the discovery of metastasis.
Fourteen patients died during the study.
B. Controls
a) Healthy subjects (107 cases) These included 57
females and 50 males (age range 18-90yrs). They
were blood donors, medical students, laboratory
staff and volunteers (geriatric institution). Seven of
them (4 females and 3 males) were studied 5 times
within 3 months.
b) Non-cancer patients (45 cases) These included
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severe clinical symptoms and critical biological and
functional impairment. They were hospitalized in
the same nursing home as the cancer patients. Some
of them suffered from diabetes (6 cases), severe
hypertension (5), pyloric stenosis (3), Crohn's
disease (3) or alcoholic cirrhosis (18) or arteritis (3);
others were gastrotomized for peptic ulcer (7). All
patients with clinical allergic symptoms were
eliminated. Nine patients (8 females and 1 male)
were studied 3 times within 1 month.
II. Histamine determination
In order to take into consideration possible diurnal
variations in blood histamine (Saavedra-Delgado et
al., 1980), blood was always taken between 9 and
10 a.m. Deionized water (800pl) and 1 ml of 0.8N
perchloric acid were added to 200p of heparinized
venous blood. After vigorous agitation, tubes were
centrifuged for 15min at 3000g and supernatants
were stored at 4°C in polystyrene tubes until assay.
All samples were analyzed in triplicate. The
histamine was assayed by the fluorometric method
of Shore et al. (1959) using Kontron
spectrofluorometer SFM 23 (wavelength accuracy,
+2nm) and an automated continuous flow
technique (Siraganian & Brodsky, 1976).
Sixty samples (200p1 each) were treated per hour.
A linear relationship was obtained from I ngml-
to 1 ,gml-1 of histamine base with good
reproducibility. The coefficient of variation of 10
whole blood histamine measurements carried out
on the same specimen was + 1% for concentrations
<2ngml- 'and <1% for higher concentrations.
In order to determine in the blood of cancer
patients, the possible presence of a substance which
might modify the fluorescence of histamine, lOng
histamine was added to 1 ml blood. In 10
determinations with blood containing initially from
10-80ng histamineml-1, the recovery of added
histamine was between 90-105%.
Results were expressed as ng histamine base ml-1
blood. Statistical analysis was by Student's t test.
III. Serum C.E.A. determination
This was performed by the immunoenzymatic
method (Abbott Laboratory). Serum C.E.A. levels
>5ngml-were considered pathological.
Results
I. Blood histamine determination
A) Population without cancer
a) Healthy subjects The mean value of blood
histamine levels was 65.1+23.2ngml-1 expressed as
histamine base (Table II), in agreement with
classical data (Vugman & Rocha e Silva, 1966).
There was no significant difference between males
and females (64.6+22.8 versus 65.5 +23.4) or
between 74 young (<60yrs) and 33 old (>60yrs)
subjects. (65.3+23.1 versus 64.8+22.9). These data
allowed us to pool all the results. In one subject,
the level was 31ngml-'. For the 7 subjects who
were studied 5 times within 3 months, the variation
in blood histamine levels was <4%.
b) Non cancer patients Blood histamine levels
(mean 59.6+22.6ngml-1) were not significantly
different from the levels of healthy subjects. In one
patient, the level was 29ngml-'. The severity of the
disease and the nutritional condition did not
influence blood histamine levels.
For the 9 patients who were studied 3 times
within 1 month, variation in blood histamine levels
was <66%. This group of patients was retained as a
control group for all statistical studies.
B) Cancer patients (Table II)
a) Group I: presence of unresected primary cancer
without known metastasis (40 patients) As a whole,
at the time of the first determination, blood
histamine levels (30.7+ 19.9ngml -') were
significantly lower than in controls (P<0.001).
The initial clinical data allowed the division into
2 subgroups. The first one included 21 patients in
whom the disease seemed relatively well-tolerated.
Initial blood histamine levels were significantly
lower than in controls (44.5+16.0ngml-1 P<0.01).
Eighteen patients remained clinically stable during
the survey and were discharged at the end of the
study. Blood histamine levels did not show
variations > 10% of the initial value during 3
months. In 3 patients, initial histamine blood levels
were 49, 52 and 62ngml-'; One month later, they
fell to 26, 25 and 38ngml-' respectively while liver
echography and chest X-rays were normal. Two
months later, metastases in the liver or in the lung
were detected and levels were 8, 7 and 16ngml-'
respectively.
In the second sub-group, 19 patients had an
advanced primary cancer. First blood histamine
levels (13.0+6.7ngml-1) were significantly lower
(P<0.001) than in the first sub-group. In all these
patients when 2 determinations within 15 days were
<15ngml-', death occurred during the following
month.
b) Group II: Presence of unresected primary tumour
and metastasis (44 patients) At the first370 C. BURTIN et al.
Table II Blood histamine levels in non cancer and in cancer patients (first determination)
Percentage of
Blood histamine levels patients with
Number of ngml-1 histamine level
Subjects mean s.d. <35 ngml-' P <
Normal subjects 107 65.1 23.2 0.9 N.S.
Non cancer patients 45 59.6 22.6 2.2
I 40 30.7 19.9 60.0 0.001
II 44 24.5 12.8 79.5 0.001
Cancer III 40 55.4 20.3 12.5 N.S.
patients* IV 39 34.1 17.1 66.7 0.001
*Groups I-IV as in Table I.
determination, there was a large decrease in blood
histamine levels: mean value: 24.5 + 12.8 ngml-'
(P<0.001 compared with control patients). In 31
patients, low initial levels (<15ngml-1) or
progressively decreasing levels were always
associated with advanced disease leading to death
within 4-8 weeks.
Conversely, when the levels were > 25ngml-'
and remained stable during the study (2-5 months),
the patients (n= 13) showed no signs of progression.
c) Group III: Patients with resected primary tumour
without known metastasis (40 patients) The first
evaluation was performed at different intervals
(between 1 month and 6 years) after surgical
excision. Whatever the interval, the mean value of
blood histamine levels was not significantly different
from the normal value.
Blood histamine levels were measured 4-6 times
in 3 months in 4 patients without clinical relapse (4
weeks, 6 weeks, 1 year and 5 years after surgery).
Variations were < 17%. In contrast, in 2 patients
initial levels were 52 and 78ngml-1, falling to 32
and 26ngml- 1 one month later. This decline
preceded the detection of hepatic metastasis and
local (cardia) relapse from one month. At that time,
blood histamine levels were 17 and 7ngml- .
d) Group IV Patients with metastasis after resection
of the primary tumour (39 patients) At the first
determination, the mean value (34.1 + 17.1 ngml-)
was significantly lower than in controls (P<0.001)
and significantly higher than in group II (patients
with primary cancer and metastasis P<0.01).
This group was subdivided into 2 subgroups. The
first included 25 patients whose disease seemed
relatively well-tolerated. The mean histamine level
was 36.2+ 17.0ngml-. Six were studied 6-8 times
within 1 year. For the same patient, variations were
s 15%.
The second subgroup included the 14 patients
who died during the study. At the first
determination, histamine levels were 30.2
+ 17.2 ngml-'. In 5 patients studied between 2
months and 15 days before death, a slight decrease
in blood histamine levels was observed.
II. Comparison between blood histamine and serum
CEA levels
Blood histamine levels and serum CEA were
determined on the same specimen from 61 patients
(Table III). Fifteen out of 19 patients with histamine
<30ngml-1 and high CEA levels died, not later
than 6 months after the evaluation. Sixteen patients
with normal histamine and CEA levels were alive 5
months after this evaluation. Thus a concordance
between histamine and CEA levels was found in
57% of patients.
Thirteen out of 21 patients with histamine
< 30ngml and normal CEA levels died during
the month following the study. Five patients with
normal histamine and high CEA levels were alive at
least 4 months after the 2 evaluations.
Among these 61 patients, 14 had colorectal
carcinomas. In 8 patients, the 2 determinations were
concordant. Three patients with normal CEA and
low histamine levels died during the study. By
contrast, 3 patients with normal histamine and
raised CEA levels were still alive 5 months after the
determination.
Discussion
This study of blood histamine levels in 163 cancer
patients emphasizes the following 5 points:
1. Mean levels were subnormal in patients whosePATIENTS WITH SOLID MALIGNANT TUMOURS
Table III Distribution of serum CEA levels (ngml-') in cancer patients with low
and normal blood histamine levels (ngml-1, mean +s.d.)
Blood histamine levels
21.6+8.4 21.2+7.4 56.4+ 12.0 60.0+ 15.8
High CEA Normal CEA High CEA Normal CEA
(6-1000) (2.1+1.2) (6-34) (1.8+0.9)
n= 19 n=21 n=5 n= 16
Group I 3 (0) 4 (0) 2 (2) 3 (0)
Group II 9 (3) 6 (0) 0 (0) 1 (0)
Group III 1 (0) 3 (1) 2 (1) 10 (3)
Group IV 6 (1) 8 (2) 1 (0) 2 (1)
Brackets indicate patients with colorectal carcinoma.
Groups I-IV as in Table I.
primary cancer had been successfully removed
(Group III). They were significantly lower in
patients with either metastasis (Group IV) or
unresected primary cancer (Group I). Lowest
values were observed in patients with both
unresected primary cancer and metastasis
(Group II).
2. These data were independent of the sex and age
of the patients, the size, localization and
histological type of tumour, and the size and
localization of metastases.
3. When the disease (primary and/or metastatic),
was well tolerated by the patient, blood
histamine levels were stable.
4. When blood histamine fell progressively, it
signified the presence of an advanced primary
cancer and/or metastases. This decrease in
histamine levels always preceded clinical relapse
or detection of metastasis by a minimum period
of one month. This fact emphasizes the
requirement for sequential histamine
determinations.
5. The comparison between CEA and histamine
levels led to the following conclusions: In
patients with colorectal carcinoma, histamine
levels of <20ngml- 1 indicated a clinical relapse
regardless of CEA levels. Surveillance of patients
after excision of colo-rectal cancer could thus
include not only the measurement of CEA but
also blood histamine determinations. For
tumours accompanied by fluctuating serum CEA
levels, blood histamine determination could be
useful as a marker for clinical progression of the
disease.
The mechanisms which induce a decrease in
blood histamine levels in patients with progressive
cancer are unknown. This decrease is not due
to reduced synthesis of histamine through lack of
histidine since plasma levels of the latter were
normal in our cancer patients whatever those of
blood histamine. Also, it is not attributable to a
reduction of leucocyte count in cancer patients since
there was no correlation between blood histamine
levels and leucocyte numbers, all of which were
within normal limits. Since in blood histamine is
almost entirely contained in basophils, decreased
levels could be due to a decreased number of
basophils and/or a decreased histamine content.
Unfortunately, the scarcity of basophils did not
allow a precise and reproducible count of these cells
when blood histamine levels were less to 40ngml- .
Whatever the mechanisms, our results emphasize
again the relations between vasoactive amines, mast
cells, basophils and cancer previously demonstrated
in vitro (Dvorak et al., 1979, Farram & Nelson,
1980) and in mice (Burtin et al., 198lb and 1982). In
man, many authors have reported the presence of
mast cells in tumours or in the vicinity of the
tumours (Asboe-Hansen, 1968; Simu & Csaba, 1972;
Maha Patro & Bowers, 1979; Hartveit, 1981). The
possible beneficial effects of type I hypersensitivity
reactions are also suggested by the negative
association between allergic diseases and malignant
tumours. In our study, none of our 163 patients had
a personal history of atopic disease.
In summary, in cancer patients a progressive fall
in blood histamine levels is indicative of progressive
primary cancer and/or the presence of metastasis.
This reduction precedes clinical relapse and/or the
detection of metastasis. Such sequential
measurement of blood histamine levels could have
clinical utility in the assessment of disease
progression.
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